Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | OGA | O60502 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12974809 | 0.88 | PTGS1 (0.46) | MEN1KMT2ACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL108228 | 0.87 | CYP3A4 (0.54) | MEN1KMT2ACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL71414 | 0.87 | PTGS1 (0.62) | MEN1KMT2ACYP3A4CYP2D6SLC6A2 | |
| SCHEMBL18589838 | 0.84 | CA12 (0.51) | MEN1KMT2ACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL24489511 | 0.83 | CYP3A4 (0.51) | MEN1KMT2ACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL10823820 | 0.83 | CYP3A4 (0.51) | MEN1KMT2ACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL1681872 | 0.83 | CYP3A4 (0.59) | MEN1KMT2ACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL13754486 | 0.83 | CYP3A4 (0.51) | MEN1KMT2ACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL20738508 | 0.83 | CYP3A4 (0.51) | MEN1KMT2ACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL12538499 | 0.83 | PTGS1 (0.46) | MEN1KMT2ACYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12044968-B2 | Protective film-forming composition having acetal structure and amide structure | NISSAN CHEMICAL CORPORATION (JP) | 2024-07-23 | — | — | US | disclosed |
| WO-2024151833-A1 | SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS, LLC (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-12030878-B2 | Substituted indole ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030878-B2 | Substituted indole ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240067638-A1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067638-A1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-29 | — | — | US | disclosed |
| US-5187173-A | Degenerative diseases such as emphysema, rheumatoid arthritis, pancreatitis, cyctic fibrosis and skin disorders | STERLING WINTHROP INC. (US) | 1993-02-16 | — | — | US | disclosed |
| EP-0281098-B1 | BENZODIOXOLE DERIVATIVES, COMPOSITIONS COMPRISING THE SAME, AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICAMENTS | Eisai Co., Ltd. (JP) | 1992-11-25 | — | — | EP | disclosed |
| EP-0483928-A1 | 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use | STERLING WINTHROP INC. (US) | 1992-05-06 | — | — | EP | disclosed |
| US-5110956-A | Liver disorders | EISAI CO., LTD. (JP) | 1992-05-05 | — | — | US | disclosed |
| EP-0281098-A1 | Benzodioxole derivatives, compositions comprising the same, and the use of the same for the manufacture of medicaments | Eisai Co., Ltd. (JP) | 1988-09-07 | — | — | EP | disclosed |
| EP-0077721-A1 | Cyclopropanecarboxylic-acid derivatives bearing an alkylthiocarbonyl group, their preparation, their use as parasiticides for plants, animals, and loci, and compositions containing them | ROUSSEL-UCLAF (FR) | 1983-04-27 | — | — | EP | disclosed |
| EP-0050534-A1 | Esters of cyclopropane-carboxylic acids related to pyrethric acid, their preparation and use as insecticides | ROUSSEL-UCLAF (FR) | 1982-04-28 | — | — | EP | disclosed |
| EP-0048186-A2 | Cyclopropane-carboxylic-acid derivatives, their preparation, their use in combating vegetal parasites, animals and locations, their compositions, and intermediates | ROUSSEL-UCLAF (FR) | 1982-03-24 | — | — | EP | disclosed |
| EP-0041021-A2 | Cyclopropane carboxylic acid derivatives, their preparation, their use against parasites in plants and animals, their compositions and their intermediates | ROUSSEL-UCLAF (FR) | 1981-12-02 | — | — | EP | disclosed |
| EP-0033259-A2 | 3-(buta-1',3'-dienyl) substituted derivatives of cyclopropane-1-carboxylic acid, compositions against the parasites of plants and warm-blooded animals, and perfuming compositions containing them; their preparation | ROUSSEL-UCLAF (FR) | 1981-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | ITGB1, ITGA1, ITGAV | MEN1 2072/4885KMT2A 3333/4885CYP3A4 2981/4885 |
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | MAT1A, AMD1, MAT2B | MEN1 525/4885KMT2A 436/4885CYP3A4 391/4885 |
| US-20240067638-A1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | MEN1 4092/4885KMT2A 1127/4885CYP3A4 4306/4885 |
| US-12030878-B2 | Substituted indole ether compounds | TLR7, TLR8, TLR1 | MEN1 3173/4885KMT2A 2860/4885CYP3A4 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.